Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models
Ezeaka Udoka C., Kim Hye Ji J., Laprairie Robert B.
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (86)
- Animal Behavior in Psychedelic Research. 2022-10-01 · Expand citations
- Effects of the 5-HT receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. 2022-06-01 · Expand citations
- Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice. 2022-06-01 · Expand citations
- The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review. 2022-06-01 · Expand citations
- Structure-based discovery of nonhallucinogenic psychedelic analogs. 2022-01-28 · Expand citations
- Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. 2022-01-01 · Expand citations
- Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. 2021-11-19 · Expand citations
- A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear. 2021-09-21 · Expand citations
- Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. 2021-08-18 · Expand citations
- Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. 2021-04-27 · Expand citations
- Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. 2021-04-22 · Expand citations
- Trial of Psilocybin versus Escitalopram for Depression. 2021-04-15 · Expand citations
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. 2021-02-03 · Expand citations
- Neuropsychological Functioning in Users of Serotonergic Psychedelics - A Systematic Review and Meta-Analysis. 2021-01-01 · Expand citations
- The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies. 2021-01-01 · Expand citations
- Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse. 2020-07-01 · Expand citations
- Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. 2020-05-01 · Expand citations
- Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. 2020-03-18 · Expand citations
- Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. 2019-08-01 · Expand citations
- Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. 2019-06-01 · Expand citations
- DARK Classics in Chemical Neuroscience: Psilocybin. 2018-10-17 · Expand citations
- Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats 2018-09-01 · Expand citations
- Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression 2017-06-19 · Expand citations
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. 2017-01-01 · Expand citations
- Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. 2016-08-01 · Expand citations
- Psychedelics. 2016-04-01 · Expand citations
- Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. 2015-01-01 · Expand citations
- The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat 2014-05-16 · Expand citations
- Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. 2013-09-01 · Expand citations
- Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS 2013-05-01 · Expand citations
- Animal models of serotonergic psychedelics. 2013-01-16 · Expand citations
- Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. 2011-11-01 · Expand citations
- Determining the pharmacokinetics of psilocin in rat plasma using ultra-performance liquid chromatography coupled with a photodiode array detector after orally administering an extract of Gymnopilus spectabilis 2011-09-01 · Expand citations
- Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. 2011-09-01 · Expand citations
- Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines 2008-10-30 · Expand citations
- Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI 2008-07-04 · Expand citations
- Psilocybin-induced stimulus control in the rat. 2007-10-01 · Expand citations
- The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. 2007-09-01 · Expand citations
- The pharmacology of psilocybin. 2002-10-01 · Expand citations
- Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man 1997-06-01 · Expand citations
- Severe aggression in rats induced by mescaline but not other hallucinogens. 1979-01-01 · Expand citations
- 10.1002/dta.2042
- 10.1007/bf02246074
- 10.1007/s00213-005-0068-6
- 10.1007/s00213-017-4716-4
- 10.1007/s00213-018-5118-y
- 10.1007/s00216-018-1558-9
- 10.1007/s11419-011-0131-4
- 10.1016/0091-3057(88)90476-5
- 10.1016/0091-3057(89)90431-0
- 10.1016/j.cell.2016.12.033
- 10.1016/j.cell.2020.08.024
- 10.1016/j.neuropharm.2011.02.006
- 10.1016/j.pbb.2004.06.012
- 10.1016/j.pbb.2005.03.022
- 10.1016/j.vascn.2013.12.004
- 10.1016/s0091-3057(97)00391-2
- 10.1016/s0140-6736(17)32802-7
- 10.1016/s0378-4347(01)00386-3
- 10.1016/s0893-133x(01)00282-2
- 10.1016/s0893-133x(97)00164-4
- 10.1021/ac00165a015
- 10.1037/0735-7044.110.3.503
- 10.1038/s41386-022-01301-9
- 10.1038/s41583-020-0367-2
- 10.1038/s41594-018-0116-7
- 10.1073/pnas.0708862105
- 10.1073/pnas.1200506109
- 10.1073/pnas.2020705118
- 10.1080/03602532.2019.1638931
- 10.1089/psymed.2022.0008
- 10.1093/jat/20.5.323
- 10.1097/fbp.0000000000000183
- 10.1111/j.1476-5381.1974.tb08611.x
- 10.1111/j.1476-5381.1979.tb07861.x
- 10.1126/science.adf0435
- 10.1177/026988110001400208
- 10.1177/0269881114531666
- 10.1177/0269881117725915
- 10.1177/02698811221104641
- 10.1177/2045125317737264
- 10.1523/jneurosci.1665-10.2010
- 10.3389/fphar.2018.00994
- 10.3389/fphar.2020.602770
- 10.4155/bio.14.260
- 10.7554/elife.35082
Cited by — these papers cite this paper (0)
No citing papers identified in the available metadata. This does not establish that none exist.